Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MMP-50
- Development stage
- Unknown
- Lead developer
- DolCas Biotech
- Administration
- Oral
01
Overview
MMP-50 is a branded dietary supplement developed by DolCas Biotech. [2, 3] It is a solvent-free, full-spectrum extract derived from the New Zealand Green Lipped Mussel (Perna canaliculus). [1] The product is marketed for joint support in both humans and pets and is standardized to inhibit matrix metalloproteinases (MMPs), which are collagen-degrading enzymes, by at least 50%. [2, 6] MMP-50 contains a range of active compounds naturally found in the mussel, including proteins, lipids, carbohydrates, omega-3 fatty acids, and glycosaminoglycans. It is supplied as a powder for oral dosage forms like capsules and is Non-GMO Project Verified. [2]
- Brand names
- MMP 50MMP50MMP-50
02
Targets
MMP12 (Macrophage Metalloelastase)
Beyond the preview
Go deeper on MMP-50.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MMP-50.